GB201510628D0 - Novel use - Google Patents

Novel use

Info

Publication number
GB201510628D0
GB201510628D0 GBGB1510628.9A GB201510628A GB201510628D0 GB 201510628 D0 GB201510628 D0 GB 201510628D0 GB 201510628 A GB201510628 A GB 201510628A GB 201510628 D0 GB201510628 D0 GB 201510628D0
Authority
GB
United Kingdom
Prior art keywords
novel use
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1510628.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Priority to GBGB1510628.9A priority Critical patent/GB201510628D0/en
Publication of GB201510628D0 publication Critical patent/GB201510628D0/en
Priority to PCT/EP2016/063795 priority patent/WO2016202882A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1510628.9A 2015-06-17 2015-06-17 Novel use Ceased GB201510628D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1510628.9A GB201510628D0 (en) 2015-06-17 2015-06-17 Novel use
PCT/EP2016/063795 WO2016202882A1 (en) 2015-06-17 2016-06-15 Fak inhibitor for treating pulmonary arterial hypertension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1510628.9A GB201510628D0 (en) 2015-06-17 2015-06-17 Novel use

Publications (1)

Publication Number Publication Date
GB201510628D0 true GB201510628D0 (en) 2015-07-29

Family

ID=53784872

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1510628.9A Ceased GB201510628D0 (en) 2015-06-17 2015-06-17 Novel use

Country Status (2)

Country Link
GB (1) GB201510628D0 (en)
WO (1) WO2016202882A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015008155A2 (en) * 2012-10-12 2017-07-04 Glaxosmithkline Llc combinations

Also Published As

Publication number Publication date
WO2016202882A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
IL281288A (en) Cryoneedle
GB201502152D0 (en) Novel use
GB201509326D0 (en) Novel use
DK3373882T3 (en) Patientisolator
GB201412290D0 (en) Novel use
GB201521751D0 (en) Novel uses
IL253635A0 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
GB201522309D0 (en) Use
GB201522311D0 (en) Use
GB201521085D0 (en) Use
GB201417497D0 (en) Novel use
GB201518466D0 (en) Use
GB201510077D0 (en) Use
GB201620095D0 (en) Novel use
GB201614590D0 (en) Novel use
GB201613185D0 (en) Novel use
GB201518831D0 (en) New use
GB201417499D0 (en) Novel use
RS63420B1 (en) Peg-binder
GB201614591D0 (en) Novel use
GB201614592D0 (en) Novel use
GB201614593D0 (en) Novel use
GB201520225D0 (en) Novel use
GB201610093D0 (en) Novel use
GB201607781D0 (en) Novel use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)